Regulation

Kesin Pharma receives approval from FDA for LIKMEZ

Kesin Pharma has received approval from the US Food and Drug Administration (FDA) for its new liquid formulation of metronidazole, LIKMEZ oral suspension, 500 mg/5 mL.

Lipella Pharmaceuticals gets ODD for LP-310 to treat GvHD

Clinical stage pharmaceutical company Lipella Pharmaceuticals has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its drug candidate, LP-310, which is intended to treat oral Graft-versus-Host Disease (GvHD).

Valneva Austria receives FDA approval for chikungunya vaccine

Valneva Austria has received approval from the US Food and Drug Administration (FDA) for Ixchiq, the first chikungunya vaccine.

Juventas receives NMPA market approval for cell therapy

CASI Pharmaceuticals’ partner Juventas Cell Therapy has received market approval from the China National Medical Products Administration (NMPA) for Inaticabtagene Autoleucel (CNCT 19).

Mirati receives approval from UK’s MHRA for NSCLC therapy

Mirati Therapeutics has received conditional marketing authorisation approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its advanced non-small cell lung cancer (NSCLC) therapy, Krazati (adagrasib).

Certa receives orphan drug designation for systemic sclerosis therapy

Certa Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational therapy, FT011, to treat systemic sclerosis (scleroderma).

UK’s NICE recommends Brukinsa to treat adults with CLL

BeiGene has received a positive recommendation from the UK’s National Institute for Health and Care Excellence (NICE) for Brukinsa (zanubrutinib) to treat adults with chronic lymphocytic leukaemia (CLL).

Hyloris’ Maxigesic IV receives FDA approval for pain management

Hyloris Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for new drug application (NDA) for Maxigesic IV to manage pain.

China accepts CANbridge’s NDA for CAN108 to treat cholestatic pruritus in PFIC

The National Medical Products Administration (NMPA) of China has accepted the new drug application (NDA) submitted by CANbridge Pharmaceuticals for CAN108 (Maralixibat Chloride Oral Solution/ LIVMARLI) for the treatment of cholestatic pruritus in patients aged two months and above with progressive familial intrahepatic cholestasis (PFIC).